Ruxolitinib Terminated Phase 1 Trials for Agnogenic Myeloid Metaplasia Treatment

TerminatedTreatment1 IdentifierTitleDrugs
NCT02436135Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease
NCT01730248A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis